Treatments & Support

Anxiety disorders are treatable. Most people are treated with talk therapy, medicine, or both. Common first medicines are selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Each card links to its source: a U.S. Food and Drug Administration (FDA) label or record, a National Institute of Mental Health (NIMH) page, or, for treatments still in clinical trials, the trial registry or company announcement.

Antidepressants and young people

Antidepressant labels carry an FDA boxed warning: in short-term studies, antidepressants increased suicidal thoughts and behaviors in children, teens, and young adults. Anyone starting a medicine or changing a dose should be watched closely, especially in the first few weeks. Never stop a medicine without talking to the prescriber.

NIMH on mental health medicines

Benzodiazepines need extra care

All benzodiazepines carry an FDA boxed warning about abuse, misuse, addiction, physical dependence, and withdrawal reactions. Taking them with opioids or alcohol can slow breathing dangerously, and stopping suddenly can cause serious withdrawal, including seizures.

FDA benzodiazepine warning

Started a medicine and still not feeling better? Antidepressants used for anxiety may take several weeks to start working, and there are next steps if the first one does not help. Source

When a medicine isn't working Anxiety and medicine log

Curious what people say online? A separate social media analysis counts how often people posting on Reddit said each anxiety medicine helped. It reflects self-selected online posts, not clinical evidence, and is not a recommendation.

What people report online

Escitalopram

FDA approved

Lexapro · a selective serotonin reuptake inhibitor (SSRI)

Generalized anxiety disorder (GAD) in adults and children 7 and older

An antidepressant from the SSRI group. SSRIs and similar antidepressants are commonly used to treat anxiety disorders.

Show details

What it is: An antidepressant from the SSRI group. SSRIs and similar antidepressants are commonly used to treat anxiety disorders.
FDA status / limitation: The Lexapro label covers generalized anxiety disorder in adults and in children 7 years and older.
Typical use: A daily tablet or liquid. Like other antidepressants used for anxiety, it may take several weeks to start working.
Safety flags: Side effects such as headaches, nausea, or trouble sleeping are usually not severe, especially when the dose starts low and rises slowly. Do not combine with monoamine oxidase inhibitors (MAOIs), and do not stop suddenly, because withdrawal symptoms can occur. Boxed warning: antidepressants increased suicidal thoughts and behaviors in children, teens, and young adults in short-term studies. Everyone starting one should be watched closely, especially in the first weeks and after dose changes.

DailyMed · Lexapro labelNational Institute of Mental Health · Generalized anxiety disorderNational Institute for Health and Care Excellence · Generalised anxiety disorder and panic disorder in adults (CG113) recommendations

Paroxetine

FDA approved

Paxil, Paxil CR · an SSRI

Panic disorder · social anxiety disorder · GAD, in adults

An SSRI antidepressant with several anxiety uses on its label.

Show details

What it is: An SSRI antidepressant with several anxiety uses on its label.
FDA status / limitation: The Paxil label covers panic disorder, social anxiety disorder, and generalized anxiety disorder in adults, along with obsessive-compulsive disorder and post-traumatic stress disorder. The extended-release Paxil CR label covers panic disorder and social anxiety disorder.
Typical use: A daily tablet. Full effect can take several weeks.
Safety flags: Side effects such as headaches, nausea, or trouble sleeping are usually not severe, especially when the dose starts low and rises slowly. Do not combine with monoamine oxidase inhibitors (MAOIs), and do not stop suddenly, because withdrawal symptoms can occur. The National Institute for Health and Care Excellence (NICE) notes paroxetine is especially likely to cause a withdrawal syndrome. Boxed warning: antidepressants increased suicidal thoughts and behaviors in children, teens, and young adults in short-term studies. Everyone starting one should be watched closely, especially in the first weeks and after dose changes.

DailyMed · Paxil (paroxetine) labelDailyMed · Paxil CR labelNational Institute for Health and Care Excellence · Generalised anxiety disorder and panic disorder in adults (CG113) recommendations

Sertraline

FDA approved

Zoloft · an SSRI

Panic disorder · social anxiety disorder, in adults

An SSRI antidepressant. NICE guidance suggests it as the first medicine to try for generalized anxiety disorder, a use that is not on the U.S. label.

Show details

What it is: An SSRI antidepressant. NICE guidance suggests it as the first medicine to try for generalized anxiety disorder, a use that is not on the U.S. label.
FDA status / limitation: The Zoloft label covers panic disorder and social anxiety disorder in adults, along with obsessive-compulsive disorder, post-traumatic stress disorder, and other conditions.
Typical use: A daily tablet or liquid. Full effect can take several weeks.
Safety flags: Side effects such as headaches, nausea, or trouble sleeping are usually not severe, especially when the dose starts low and rises slowly. Do not combine with monoamine oxidase inhibitors (MAOIs), and do not stop suddenly, because withdrawal symptoms can occur. Boxed warning: antidepressants increased suicidal thoughts and behaviors in children, teens, and young adults in short-term studies. Everyone starting one should be watched closely, especially in the first weeks and after dose changes.

DailyMed · Zoloft labelNational Institute for Health and Care Excellence · Generalised anxiety disorder and panic disorder in adults (CG113) recommendations

Fluoxetine

FDA approved

Prozac · an SSRI

Panic disorder, with or without agoraphobia, in adults

One of the most widely used SSRI antidepressants.

Show details

What it is: One of the most widely used SSRI antidepressants.
FDA status / limitation: The Prozac label covers panic disorder with or without agoraphobia, along with obsessive-compulsive disorder and other conditions.
Typical use: A daily capsule. Full effect can take several weeks.
Safety flags: Side effects such as headaches, nausea, or trouble sleeping are usually not severe, especially when the dose starts low and rises slowly. Do not combine with monoamine oxidase inhibitors (MAOIs), and do not stop suddenly, because withdrawal symptoms can occur. Boxed warning: antidepressants increased suicidal thoughts and behaviors in children, teens, and young adults in short-term studies. Everyone starting one should be watched closely, especially in the first weeks and after dose changes.

DailyMed · Prozac label

Venlafaxine extended-release

FDA approved

Effexor XR · a serotonin-norepinephrine reuptake inhibitor (SNRI)

GAD · social anxiety disorder · panic disorder, in adults

An antidepressant from the SNRI group, used alongside SSRIs for anxiety disorders.

Show details

What it is: An antidepressant from the SNRI group, used alongside SSRIs for anxiety disorders.
FDA status / limitation: The Effexor XR label covers generalized anxiety disorder, social anxiety disorder, and panic disorder in adults.
Typical use: A daily capsule. Full effect can take several weeks.
Safety flags: Side effects such as headaches, nausea, or trouble sleeping are usually not severe, especially when the dose starts low and rises slowly. Do not combine with monoamine oxidase inhibitors (MAOIs), and do not stop suddenly, because withdrawal symptoms can occur. NICE notes venlafaxine is especially likely to cause a withdrawal syndrome and is more dangerous in overdose. Boxed warning: antidepressants increased suicidal thoughts and behaviors in children, teens, and young adults in short-term studies. Everyone starting one should be watched closely, especially in the first weeks and after dose changes.

DailyMed · Effexor XR labelNational Institute for Health and Care Excellence · Generalised anxiety disorder and panic disorder in adults (CG113) recommendations

Duloxetine

FDA approved

Cymbalta and generic duloxetine · an SNRI

GAD in adults and children 7 and older

An SNRI antidepressant that is also used for some kinds of long-lasting pain.

Show details

What it is: An SNRI antidepressant that is also used for some kinds of long-lasting pain.
FDA status / limitation: The duloxetine label covers generalized anxiety disorder in adults and in children 7 years and older, along with several pain conditions.
Typical use: A daily capsule. Full effect can take several weeks.
Safety flags: Side effects such as headaches, nausea, or trouble sleeping are usually not severe, especially when the dose starts low and rises slowly. Do not combine with monoamine oxidase inhibitors (MAOIs), and do not stop suddenly, because withdrawal symptoms can occur. Boxed warning: antidepressants increased suicidal thoughts and behaviors in children, teens, and young adults in short-term studies. Everyone starting one should be watched closely, especially in the first weeks and after dose changes.

DailyMed · Duloxetine delayed-release capsules label

Buspirone

FDA approved

generic buspirone

Anxiety disorders · short-term relief of anxiety symptoms

A different type of anti-anxiety medicine that NIMH says can be used to treat anxiety over longer periods.

Show details

What it is: A different type of anti-anxiety medicine that NIMH says can be used to treat anxiety over longer periods.
FDA status / limitation: The label covers the management of anxiety disorders and short-term relief of anxiety symptoms.
Typical use: Taken every day. It needs 3 to 4 weeks to reach full effect and does not work on an as-needed basis.
Safety flags: The most common side effects on the label are dizziness, drowsiness, nausea, headache, and nervousness. Do not take it with an MAOI or within 14 days of stopping one.

DailyMed · Buspirone tablets labelNational Institute of Mental Health · Mental health medicationsMedlinePlus · Buspirone

Hydroxyzine

FDA approved

generic hydroxyzine hydrochloride · an antihistamine

Symptom relief of anxiety and tension

An antihistamine. MedlinePlus lists relieving anxiety and tension among its uses, along with itching from allergic skin reactions and sedation around surgery.

Show details

What it is: An antihistamine. MedlinePlus lists relieving anxiety and tension among its uses, along with itching from allergic skin reactions and sedation around surgery.
FDA status / limitation: The label covers symptom relief of anxiety and tension linked to psychoneurosis, and says its effectiveness for longer than 4 months has not been studied.
Typical use: Taken as directed by the prescriber. Ask how often to take it and for how long.
Safety flags: Can cause drowsiness and dry mouth, and adds to the effect of alcohol and other medicines that slow the brain. The label warns about a heart rhythm problem called QT prolongation and says not to use it in early pregnancy.

DailyMed · Hydroxyzine hydrochloride tablets labelMedlinePlus · HydroxyzineMedlinePlus · Generalized anxiety disorder

Beta-blockers

Off-label use

heart medicines prescribed off-label

Short-term physical symptoms, such as performance anxiety

Heart and blood pressure medicines that can calm a racing heart, sweating, and trembling.

Show details

What it is: Heart and blood pressure medicines that can calm a racing heart, sweating, and trembling.
FDA status / limitation: Not approved for anxiety. The National Institute of Mental Health (NIMH) says providers may prescribe them off-label for short-term anxiety symptoms, and that they are commonly the medicine of choice for the performance anxiety type of social anxiety disorder.
Typical use: Taken as needed before a situation that sets off physical symptoms.
Safety flags: Generally not recommended for people with asthma or diabetes, because they may worsen both conditions.

National Institute of Mental Health · Mental health medicationsNational Institute of Mental Health · Social anxiety disorder

Benzodiazepines

FDA approved · boxed warning

alprazolam (Xanax), clonazepam (Klonopin), lorazepam (Ativan), diazepam (Valium), and others

Alprazolam: GAD and panic disorder · clonazepam: panic disorder · lorazepam and diazepam: anxiety disorders

Sedative anti-anxiety medicines that work quickly. Because tolerance and dependence can develop, providers may prescribe them only for brief periods.

Show details

What it is: Sedative anti-anxiety medicines that work quickly. Because tolerance and dependence can develop, providers may prescribe them only for brief periods.
FDA status / limitation: Each label lists its own anxiety uses, as shown above. The U.S. Food and Drug Administration (FDA) requires a boxed warning on all benzodiazepines about abuse, misuse, addiction, physical dependence, and withdrawal reactions. NICE advises against them for generalized anxiety disorder except briefly in a crisis, and against them for panic disorder.
Typical use: Usually short-term or as needed, at the lowest dose that works, with regular check-ins.
Safety flags: Physical dependence can develop after several days to weeks, even as prescribed. Stopping suddenly or cutting the dose too fast can cause withdrawal reactions, including seizures, so any taper should be slow and planned with the prescriber. Combining them with opioids, alcohol, or other sedating medicines can cause severe breathing problems and death.

U.S. Food and Drug Administration · Boxed Warning updated for benzodiazepines (Sep 23, 2020)DailyMed · Xanax labelDailyMed · Klonopin labelDailyMed · Ativan tablets labelDailyMed · Valium labelNational Institute of Mental Health · Generalized anxiety disorderNational Institute for Health and Care Excellence · Generalised anxiety disorder and panic disorder in adults (CG113) recommendations

Cognitive behavioral therapy (CBT)

Evidence-based · first choice

talk therapy, in person or by telehealth

GAD · panic disorder · social anxiety disorder · phobias

A therapy that helps people notice anxious or unhelpful automatic thoughts, question them, and change the behaviors that keep anxiety going. NIMH calls CBT the gold standard therapy for generalized anxiety disorder and social anxiety disorder.

Show details

What it is: A therapy that helps people notice anxious or unhelpful automatic thoughts, question them, and change the behaviors that keep anxiety going. NIMH calls CBT the gold standard therapy for generalized anxiety disorder and social anxiety disorder.
FDA status / limitation: There is no FDA approval process for psychotherapies. NIMH lists CBT as research-supported for each major anxiety disorder. NICE recommends individual CBT, usually 12 to 15 weekly one-hour sessions for generalized anxiety disorder, with applied relaxation as an alternative.
Typical use: One-on-one or in a group, in person or online. Group CBT can offer extra benefits for social anxiety.
Safety flags: Finding a therapist you trust matters. It is fine to ask about their training and approach before starting.

National Institute of Mental Health · Generalized anxiety disorderNational Institute of Mental Health · Social anxiety disorderNational Institute for Health and Care Excellence · Generalised anxiety disorder and panic disorder in adults (CG113) recommendationsNational Institute for Health and Care Excellence · Social anxiety disorder (CG159) recommendations

Exposure therapy

Evidence-based

a type of CBT

Panic disorder · social anxiety disorder · phobias

Facing feared situations, objects, or body sensations step by step in a supportive setting, from least to most frightening, until the fear fades. For panic, interoceptive exposure practices the body sensations of a panic attack.

Show details

What it is: Facing feared situations, objects, or body sensations step by step in a supportive setting, from least to most frightening, until the fear fades. For panic, interoceptive exposure practices the body sensations of a panic attack.
FDA status / limitation: NIMH describes exposure therapy as a CBT method for anxiety disorders. MedlinePlus lists exposure-based treatment among the talk therapies often tried first for specific phobias.
Typical use: Practiced with a therapist and between sessions. It may be combined with relaxation exercises.
Safety flags: It is meant to feel uncomfortable but manageable. Work at a pace agreed with the therapist.

National Institute of Mental Health · Panic disorderNational Institute of Mental Health · PsychotherapiesMedlinePlus · Phobia, simple or specific

Acceptance and commitment therapy (ACT)

Growing evidence

talk therapy

GAD · social anxiety disorder

A therapy that encourages accepting thoughts and feelings without judging them, and committing to meaningful activities. It uses mindfulness and goal setting.

Show details

What it is: A therapy that encourages accepting thoughts and feelings without judging them, and committing to meaningful activities. It uses mindfulness and goal setting.
FDA status / limitation: NIMH says a growing body of research shows it works for generalized anxiety disorder and social anxiety disorder.
Typical use: One-on-one or in a group, with a trained therapist.
Safety flags: Ask the therapist how progress will be measured.

National Institute of Mental Health · Generalized anxiety disorderNational Institute of Mental Health · Social anxiety disorder

Prescription therapy app

FDA cleared · 2024

Daylight (Big Health)

GAD in adults 22 and older, alongside usual care

A smartphone app that delivers CBT techniques for generalized anxiety disorder.

Show details

What it is: A smartphone app that delivers CBT techniques for generalized anxiety disorder.
FDA status / limitation: FDA cleared Daylight on August 30, 2024, as a prescription digital therapeutic to improve generalized anxiety disorder symptoms as an add-on to usual care in adults 22 and older. It was tested in a trial of 351 adults against online anxiety education.
Typical use: Available on the order of a licensed health care provider, who can follow progress through an online portal. It adds to care; it does not replace a clinician.
Safety flags: Not for emergencies. Contact a clinician or 988 if anxiety gets worse or thoughts of self-harm appear.

U.S. Food and Drug Administration · 510(k) premarket notification K233872 (Daylight, Big Health)

Breathing biofeedback device

FDA cleared · 2018, expanded 2025

Freespira

Symptoms of panic disorder · stress and anxiety symptoms in teens 13 to 17

A system that leads the user through guided, monitored breathing exercises.

Show details

What it is: A system that leads the user through guided, monitored breathing exercises.
FDA status / limitation: FDA cleared Freespira on August 23, 2018, as an add-on treatment for symptoms of panic disorder and post-traumatic stress disorder. A clearance on April 25, 2025, added teens 13 to 17 for symptoms of stress and anxiety.
Typical use: Prescription only, used under the direction of a health care professional together with other treatment.
Safety flags: An add-on, not a replacement for therapy or medicine.

U.S. Food and Drug Administration · 510(k) premarket notification K180173 (Freespira)U.S. Food and Drug Administration · 510(k) premarket notification K233337 (Freespira Breathing System)

DT120 (LSD tablet)

Phase 3 · not FDA approved

lysergide (lysergic acid diethylamide), formerly MM120 (Definium Therapeutics)

GAD in adults

A dissolving tablet (orally disintegrating tablet, or ODT) form of LSD, a psychedelic, tested as a single supervised dose.

Show details

What it is: A dissolving tablet (orally disintegrating tablet, or ODT) form of LSD, a psychedelic, tested as a single supervised dose.
Access boundary: Not FDA approved. Available only to people enrolled in a clinical trial. Not something to buy, order online, or try on your own.
Where it stands: Status as of September 2026: the company reported two positive Phase 3 trials in generalized anxiety disorder, Voyage (August 12, 2026) and Panorama (September 14, 2026). It plans to meet FDA in late 2026 and expects to file for approval in the first half of 2027 (company projection).
Typical use: Only given within clinical trials today. In Panorama, people were monitored for at least 8 hours on dosing day.
Safety flags: A psychedelic that causes temporary changes in perception and thinking, so trial doses are given under medical supervision. The company reports mostly mild to moderate side effects on the dosing day and no suicidality signal. Safety is still being studied.

Definium Therapeutics · Positive Phase 3 Panorama results for DT120 in generalized anxiety disorder (Sep 14, 2026)Definium Therapeutics · Positive Phase 3 Voyage results for DT120 in generalized anxiety disorder (Aug 12, 2026)

Ulotaront

Phase 3 · not FDA approved

SEP-363856 (Otsuka)

GAD in adults

A daily pill being tested against placebo over 8 weeks for generalized anxiety disorder.

Show details

What it is: A daily pill being tested against placebo over 8 weeks for generalized anxiety disorder.
Access boundary: Not FDA approved. Available only to people enrolled in a clinical trial. Not something to buy, order online, or try on your own.
Where it stands: Status as of October 2026 (trial registry): two Phase 3 trials, planning about 576 and 384 adults, began recruiting in mid-2026. Main results are estimated in late 2028.
Typical use: Only given within clinical trials today.
Safety flags: Safety for this use is still being studied. Ask the trial team about risks.

ClinicalTrials.gov · NCT07759128 (ulotaront, SEP-363856)ClinicalTrials.gov · NCT07767903 (ulotaront, SEP-363856)

VQW-765

Phase 3 · not FDA approved

Vanda Pharmaceuticals

On-demand treatment of social anxiety disorder in adults 18 to 65

A capsule tested as a single dose, compared with placebo.

Show details

What it is: A capsule tested as a single dose, compared with placebo.
Access boundary: Not FDA approved. Available only to people enrolled in a clinical trial. Not something to buy, order online, or try on your own.
Where it stands: Status as of October 2026 (trial registry): a Phase 3 trial of about 500 adults has finished recruiting, with main results estimated in December 2026. No results have been posted yet.
Typical use: Only given within clinical trials today.
Safety flags: Safety is still being studied. Ask the trial team about risks.

ClinicalTrials.gov · NCT07221578 (VQW-765)

ITI-1284

Phase 3 starting · not FDA approved

JNJ-99245354 (Intra-Cellular Therapies, Johnson & Johnson)

Added to current treatment for GAD that has not responded well enough

A once-daily pill being tested as an add-on for adults whose generalized anxiety disorder has not improved enough with their current treatment.

Show details

What it is: A once-daily pill being tested as an add-on for adults whose generalized anxiety disorder has not improved enough with their current treatment.
Access boundary: Not FDA approved. Available only to people enrolled in a clinical trial. Not something to buy, order online, or try on your own.
Where it stands: Status as of October 2026 (trial registry): an add-on Phase 3 trial of about 705 adults is listed as not yet recruiting, and a long-term Phase 3 safety study is recruiting.
Typical use: Only given within clinical trials today.
Safety flags: Safety is still being studied. Ask the trial team about risks.

ClinicalTrials.gov · NCT07856420 (ITI-1284, JNJ-99245354)ClinicalTrials.gov · NCT07807865 (ITI-1284 long-term safety)

Medicine names, uses, and warnings come from FDA labels on DailyMed, FDA device records and safety pages, NIMH, MedlinePlus, and NICE guidance. Cards marked In clinical trials cite the trial registry or the company's own announcement, and company plans can change. Status was checked on October 8, 2026. Labels change; check the linked source for the latest.

Everyday habits

Things that can help alongside treatment

Healthy habits that NIMH and MedlinePlus describe. They can help alongside care; they are not a substitute for diagnosis or treatment.

Talk with a health care provider before starting any supplement or making big changes.

Caffeine and sleep

NIMH healthy habits

Cutting back on caffeine and getting enough sleep can reduce anxiety symptoms.

Researchers found these choices helped when paired with standard care such as psychotherapy and medicine.

Healthy habits alone cannot replace treatment.

National Institute of Mental Health · Generalized anxiety disorder

Exercise, mindfulness, and meditation

NIMH healthy habits

Stress management techniques can ease anxiety and boost the effects of psychotherapy.

Ask a health care provider how these fit with your treatment plan.

Start where you are. Small, regular steps count.

National Institute of Mental Health · Generalized anxiety disorder

Alcohol and drugs

What to avoid

Avoid street drugs and large amounts of alcohol.

MedlinePlus lists this among the self-care steps that can help. If you are prescribed a sedative, do not drink alcohol while taking it.

If substance use is part of the picture, see the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline on the Resources page.

MedlinePlus · Generalized anxiety disorder

Routine

MedlinePlus self-care

Keep a regular schedule and get out of the house every day.

Exercising, getting enough rest, and eating healthy foods are part of the self-care MedlinePlus lists for generalized anxiety disorder.

Small daily routines make it easier to keep facing situations instead of avoiding them.

MedlinePlus · Generalized anxiety disorder

Support groups

Connection

Sharing with others who have similar experiences can help.

Groups meet in person and online. For social anxiety, a group can offer honest feedback that challenges fears about being judged.

Advice from group members does not replace treatment recommendations from a provider.

National Institute of Mental Health · Social anxiety disorder

Clinical trials

Anxiety studies looking for volunteers

1,208 anxiety studies were recruiting on ClinicalTrials.gov as of October 8, 2026. Below are 50 of them, each with at least one site in the United States, picked to cover different anxiety disorders, age groups, and kinds of treatment: medicines, therapy, and devices.

Talk with your doctor before joining a trial

A listing here is not a recommendation. Studies test treatments that may not work or may have side effects, and each one has its own rules about who can join. Ask your doctor, or your child's doctor, whether a study fits, and keep taking current treatment unless your care team says otherwise. A research study is not emergency care: in a crisis, call or text 988.

Find a study near you

This opens ClinicalTrials.gov with recruiting anxiety studies already selected. Type your city or ZIP code in the Location box to see studies close to home.

Search recruiting anxiety studies

Studies run by NIMH at the National Institutes of Health (NIH) campus in Bethesda, Maryland

Adults with anxiety disorders Children with anxiety disorders How clinical trials work (NIMH)

Type of anxiety

Kind of treatment

Phase

RecruitingPhase 2Medicine or supplement

ITI-1284 as an add-on in people with generalized anxiety disorder

Generalized anxiety

What is tested:: ITI-1284 10 mg, ITI-1284 20 mg
Who can join:: Any age · Generalized Anxiety Disorder
Where:: 25 US sites in California, Florida, Texas and 8 more states · also Bulgaria, Czechia, Poland and 1 more country
Sponsor:: Intra-Cellular Therapies, Inc

Titles on ClinicalTrials.gov

Brief title: Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment

NCT06480383 on ClinicalTrials.gov

RecruitingPhase 2Medicine or supplement

ITI-1284 on its own in people with generalized anxiety disorder

Generalized anxiety

What is tested:: ITI-1284 10 mg, ITI-1284 20 mg
Who can join:: Ages 18 and older · Generalized Anxiety Disorder
Where:: 25 US sites in California, Florida, New York and 10 more states · also Bulgaria, Poland, Serbia and 1 more country
Sponsor:: Intra-Cellular Therapies, Inc

Titles on ClinicalTrials.gov

Brief title: Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder Who Have Had Inadequate Response to Generalized Anxiety Disorder Treatment

NCT06701903 on ClinicalTrials.gov

RecruitingPhase 2Medicine or supplement

Oral ABBV-932 added to antidepressant therapies in adults with generalized anxiety disorder

Generalized anxiety

What is tested:: ABBV-932, Antidepressant Therapy (ADT)
Who can join:: Ages 18 to 65 · Generalized Anxiety Disorder (GAD)
Where:: 49 US sites in California, Florida, Texas and 19 more states · also Puerto Rico
Sponsor:: AbbVie

Titles on ClinicalTrials.gov

Brief title: Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies

NCT06846320 on ClinicalTrials.gov

RecruitingPhase 3Medicine or supplement

Fixed doses of SEP-363856 in adults with generalized anxiety disorder

Generalized anxiety

What is tested:: SEP-363856
Who can join:: Ages 18 and older · Generalized Anxiety Disorder
Where:: 6 US sites in Florida, Arizona, Nevada and 2 more states
Sponsor:: Otsuka Pharmaceutical Development & Commercialization, Inc

Titles on ClinicalTrials.gov

Brief title: A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

Official title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Compare the Efficacy and Safety of Fixed Doses of SEP-363856 to Placebo in the Treatment of Adults With Generalized Anxiety Disorder

NCT07759128 on ClinicalTrials.gov

RecruitingPhase 3Medicine or supplement

A fixed dose of SEP-363856 in adults with generalized anxiety disorder

Generalized anxiety

What is tested:: SEP-363856
Who can join:: Ages 18 and older · Generalized Anxiety Disorder
Where:: 5 US sites in California, Florida, New Jersey and 2 more states
Sponsor:: Otsuka Pharmaceutical Development & Commercialization, Inc

Titles on ClinicalTrials.gov

Brief title: A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

Official title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Compare the Efficacy and Safety of a Fixed Dose of SEP-363856 to Placebo in the Treatment of Adults With Generalized Anxiety Disorder

NCT07767903 on ClinicalTrials.gov

RecruitingPhase 2Medicine or supplement

NTX-1472 in social anxiety disorder

Social anxiety

What is tested:: NTX-1472
Who can join:: Ages 18 to 65 · Social Anxiety Disorder (SAD)
Where:: 11 US sites in California, Florida, Massachusetts and 4 more states
Sponsor:: Newleos Therapeutics, Inc

Titles on ClinicalTrials.gov

Brief title: A Study of NTX-1472 in Social Anxiety Disorder

Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder

NCT07323784 on ClinicalTrials.gov

RecruitingPhase 3Medicine or supplement

Cannabidiol-assisted learning for managing generalized anxiety disorder

Generalized anxiety

What is tested:: Low-Dose Cannabidiol, Moderate-Dose Cannabidiol
Who can join:: Ages 18 to 45 · Generalized Anxiety Disorder (GAD), Anxiety Disorders
Where:: 1 US site in Michigan
Sponsor:: Wayne State University

Titles on ClinicalTrials.gov

Brief title: Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

Official title: Cannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety Disorder

NCT07123467 on ClinicalTrials.gov

RecruitingPhase 2Therapy, behavioral, or digitalMedicine or supplement

Neuro-cognitive correlates of pediatric anxiety disorders

Children and teens · Anxiety in general or mixed

What is tested:: Attention Bias Modification Training, Fluoxetine, Cognitive Behavioral Therapy
Who can join:: Ages 8 to 65 · Anxiety Disorders, Major Depressive Disorder
Where:: 2 US sites in Maryland
Sponsor:: National Institute of Mental Health (NIMH)

Titles on ClinicalTrials.gov

Brief title: Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders

Official title: Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders

NCT00018057 on ClinicalTrials.gov

RecruitingPhase 2Therapy, behavioral, or digital

Gaze-contingent music therapy augmentation of CBT for pediatric anxiety

Children and teens · Anxiety in general or mixed

What is tested:: Gaze-Contingent Music Reward Therapy
Who can join:: Ages 8 to 17 · Psychiatric Disorders, Anxiety Disorders
Where:: 1 US site in Maryland
Sponsor:: National Institute of Mental Health (NIMH)

Titles on ClinicalTrials.gov

Brief title: Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety

Official title: Phase II Efficacy Study of Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety

NCT06595953 on ClinicalTrials.gov

RecruitingPhase 2Medicine or supplement

A new intervention to improve function in veterans with anxiety and depression

With another health condition · Anxiety in general or mixed

What is tested:: Pregnenolone
Who can join:: Ages 18 to 65 · Anxiety and Depression
Where:: 1 US site in North Carolina
Sponsor:: U.S. Department of Veterans Affairs (VA) Office of Research and Development

Titles on ClinicalTrials.gov

Brief title: A New Intervention to Improve Function in Veterans With Anxiety and Depression

Official title: A New Intervention to Improve Function in Veterans With Anxiety and Depression

NCT06188923 on ClinicalTrials.gov

RecruitingPhase 2Medicine or supplement

A mechanistic study to assess a single dose of CYB003 in people with depression and anxiety

Anxiety in general or mixed

What is tested:: CYB003
Who can join:: Ages 21 to 65 · Depression, Anxiety
Where:: 1 US site in Ohio
Sponsor:: Ohio State University

Titles on ClinicalTrials.gov

Brief title: A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

Official title: A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

NCT06820723 on ClinicalTrials.gov

RecruitingPhase 4Medicine or supplement

Processes and circuitry underlying threat sensitivity as a treatment target for co-morbid anxiety and depression

Anxiety in general or mixed

What is tested:: Lorazepam
Who can join:: Ages 18 to 65 · Depression, Anxiety, Fear
Where:: 1 US site in Oklahoma
Sponsor:: Laureate Institute for Brain Research, Inc

Titles on ClinicalTrials.gov

Brief title: Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

Official title: Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

NCT06004115 on ClinicalTrials.gov

RecruitingPhase 4Medicine or supplement

Effects of cannabidiol on social anxiety disorder

Social anxiety

What is tested:: Cannabidiol
Who can join:: Ages 18 to 55 · Phobia, Social
Where:: 1 US site in Massachusetts
Sponsor:: Massachusetts Institute of Technology

Titles on ClinicalTrials.gov

Brief title: Investigating the Effects of Cannabidiol on Social Anxiety Disorder

Official title: Investigating the Effects of Cannabidiol on Social Anxiety Disorder

NCT05649059 on ClinicalTrials.gov

RecruitingPhase 4Medicine or supplement

Caplyta vs placebo for adults with social anxiety disorder

Social anxiety

What is tested:: Lumateperone 42 mg
Who can join:: Ages 18 to 65 · Social Anxiety Disorder (SAD)
Where:: 1 US site in New York
Sponsor:: Jason Careri

Titles on ClinicalTrials.gov

Brief title: Caplyta Versus Placebo for Adults With Social Anxiety Disorder

Official title: Caplyta® in the Treatment of Social Anxiety Disorder: A Double-Blind Study

NCT07799493 on ClinicalTrials.gov

RecruitingPhase 4Medicine or supplement

Buspirone for anxiety in autistic youth

Children and teens · Anxiety in general or mixed

What is tested:: buspirone
Who can join:: Ages 7 to 17 · Anxiety, Autism Spectrum Disorder
Where:: 1 US site in Massachusetts
Sponsor:: Massachusetts General Hospital

Titles on ClinicalTrials.gov

Brief title: Buspirone for Anxiety in Autistic Youth

Official title: A Randomized Controlled Trial of Buspirone for Anxiety in Autistic Youth

NCT07439042 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Cultural adaptation of a single-session intervention (SSI) for youth anxiety

Children and teens · Anxiety in general or mixed

What is tested:: Adapted Project BRAVE
Who can join:: Ages 18 and older · Anxiety Disorders
Where:: 1 US site in Florida
Sponsor:: University of Miami

Titles on ClinicalTrials.gov

Brief title: Cultural Adaptation of a SSI for Youth Anxiety

Official title: Cultural Adaptation and Dissemination of a Single-Session Intervention (SSI) Targeting Caregivers of Youth With Anxiety

NCT04729504 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Anxiety sensitivity treatment to reduce anxiety in Alzheimer's

Older adults · Anxiety in general or mixed

What is tested:: Computerized Anxiety Sensitivity Treatment, Health Education Control
Who can join:: Ages 60 and older · Anxiety, Mild Cognitive Impairment
Where:: 3 US sites in Ohio, Florida
Sponsor:: Florida State University

Titles on ClinicalTrials.gov

Brief title: Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's

Official title: Treatment of Stress and Anxiety in Mild Cognitive Impairment/Mild Alzheimer's Disease and Related Dementias - RCT

Abbreviations: RCT means randomized controlled trial

NCT05748613 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Screening and treatment for anxiety and depression (S.T.A.N.D.): Alacrity Center signature project

Anxiety in general or mixed

What is tested:: Self-Guided Online Prevention, Coach-Guided Online Cognitive Behavioral Therapy, Clinician-Delivered Psychological and Psychiatric Care
Who can join:: Ages 18 to 40 · Depression, Anxiety
Where:: 1 US site in California
Sponsor:: University of California, Los Angeles

Titles on ClinicalTrials.gov

Brief title: S.T.A.N.D. Alacrity Center Signature Project

Official title: Screening and Treatment for Anxiety & Depression (S.T.A.N.D): Alacrity Center Signature Project on Triaging and Adapting to Level of Care

NCT05591937 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Behavioral exposure for interoceptive tolerance, a randomized controlled trial (RCT)

With another health condition · Anxiety in general or mixed

What is tested:: Behavioral Exposure For Introceptive Tolerance, Health Education Control
Who can join:: Ages 40 and older · Exercise Sensitivity, Introceptive Exposure
Where:: 3 US sites in New Jersey
Sponsor:: Rutgers, The State University of New Jersey

Titles on ClinicalTrials.gov

Brief title: Behavioral Exposure for Introceptive Tolerance RCT

Official title: A Tailored Exposure Intervention for Exercise Anxiety and Avoidance in Cardiac Rehabilitation

NCT05398276 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Grow with Grit: a school nurse-led screening, brief intervention, and referral to treatment (SBIRT) pilot for early anxiety detection

Children and teens · Anxiety in general or mixed

What is tested:: Grow with Grit
Who can join:: Ages 8 to 12 · Anxiety
Where:: 4 US sites in Montana
Sponsor:: McLaughlin Research Institute for Biomedical Sciences, Inc

Titles on ClinicalTrials.gov

Brief title: Grow With Grit: A School Nurse-Led SBIRT Pilot for Early Anxiety Detection

Official title: Grow With Grit: A Nurse-Led SBIRT Model for Early Anxiety Detection and School-Based Mental Health Intervention in Rural Youth

NCT07766785 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Anxiety skills study

Generalized anxiety · Panic and agoraphobia · Social anxiety · Specific phobias

What is tested:: Cognitive therapy, Behavioral therapy, Mindfulness-based therapy
Who can join:: Ages 18 and older · Anxiety, Anxiety Acute
Where:: 1 US site in Ohio
Sponsor:: Ohio State University

Titles on ClinicalTrials.gov

Brief title: Anxiety Skills Study

Official title: Personalizing and Optimizing CBT Skills for Anxiety

NCT07774481 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Role of parent interpretation bias in the transmission of anxiety to children

Children and teens · Anxiety in general or mixed

What is tested:: HabitWorks, Self-Assessment
Who can join:: Ages 7 and older · Anxiety
Where:: 1 US site in Massachusetts
Sponsor:: Mclean Hospital

Titles on ClinicalTrials.gov

Brief title: Role of Parent Interpretation Bias in the Transmission of Anxiety to Children

Official title: Parent Interpretation Bias as a Key Mechanism of Intergenerational Transmission of Anxiety

NCT05665491 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digitalBrain stimulation, device, or app

Transcranial photobiomodulation in anxiety disorders

Anxiety in general or mixed

What is tested:: Attention bias assessment and modification, Transcranial photobiomodulation
Who can join:: Ages 18 to 100 · Symptoms of Anxiety
Where:: 1 US site in Texas
Sponsor:: Francisco Gonzalez-Lima, PhD

Titles on ClinicalTrials.gov

Brief title: Transcranial Photobiomodulation in Anxiety Disorders

Official title: Effects of Transcranial Photobiomodulation and Attention Bias Modification on Anxiety Symptoms and Brain Hemodynamics

NCT07133893 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Comparing transdiagnostic behavior therapy (TBT) to disorder-specific psychotherapy in veterans with social anxiety disorder

Social anxiety

What is tested:: Transdiagnostic Behavior Therapy, Cognitive Behavioral Therapy for Social Anxiety Disorder
Who can join:: Ages 18 to 80 · Social Anxiety Disorder
Where:: 1 US site in South Carolina
Sponsor:: U.S. Department of Veterans Affairs (VA) Office of Research and Development

Titles on ClinicalTrials.gov

Brief title: Comparing TBT to Disorder-Specific Psychotherapy in Veterans With Social Anxiety Disorder

Official title: A Randomized Clinical Trial Comparing Transdiagnostic Behavior Therapy to Disorder-Specific Psychotherapy in the Recovery of Veterans With Social Anxiety Disorder and Comorbid PTSD Symptomatology

Abbreviations: PTSD means post-traumatic stress disorder

NCT05858346 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Brain stimulation, device, or app

Low-intensity focused ultrasound pulsation (LIFUP) for generalized anxiety disorder

Generalized anxiety

What is tested:: Active LIFUP Treatment
Who can join:: Ages 18 to 65 · Generalized Anxiety Disorder
Where:: 3 US sites in California, Massachusetts, South Carolina
Sponsor:: University of California, Los Angeles

Titles on ClinicalTrials.gov

Brief title: Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)

Official title: Feasibility of Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)

NCT04557891 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Reward processing and exposure therapy for social anxiety disorder

Social anxiety

What is tested:: Positive Affect Treatment - Behavioral (PAT-B), Relaxation Treatment, Exposure Therapy
Who can join:: Ages 18 to 60 · Social Anxiety Disorder (Social Phobia), Public Speaking Anxiety
Where:: 2 US sites in California
Sponsor:: University of California, Los Angeles

Titles on ClinicalTrials.gov

Brief title: Reward Processing and Exposure Therapy for Social Anxiety Disorder

Official title: Reward Processing and Exposure Therapy

NCT06776991 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Brain stimulation, device, or app

Device for treating generalized anxiety

Generalized anxiety

What is tested:: EXOMIND (BTL-699-2) Active treatment
Who can join:: Ages 22 and older · Generalized Anxiety Disorder (GAD)
Where:: 3 US sites in Colorado, Illinois, Indiana
Sponsor:: BTL Industries Ltd

Titles on ClinicalTrials.gov

Brief title: Device for Treating Generalized Anxiety

Official title: Evaluation of the Efficacy and Safety of an Accelerated Protocol for Treating Generalized Anxiety Disorder Using the BTL-699-2 Device

NCT07819773 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Brain stimulation, device, or appTherapy, behavioral, or digital

Respiratory training for transdiagnostic pathological anxiety

Generalized anxiety · Panic and agoraphobia · Social anxiety

What is tested:: Capnometry-Guided Respiratory Intervention, Psycho-Education
Who can join:: Ages 18 and older · Anxiety Disorders, Trauma
Where:: 1 US site in Texas
Sponsor:: University of Texas at Austin

Titles on ClinicalTrials.gov

Brief title: Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety

Official title: Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety: A Randomized Clinical Trial

NCT05427708 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Brain stimulation, device, or appTherapy, behavioral, or digital

Intracranial neurophysiological signatures of fear and anxiety in people

Generalized anxiety

What is tested:: Deep Brain Stimulation, Virtual and augmented reality tasks
Who can join:: Ages 18 to 70 · Fear, GAD
Where:: 2 US sites in California, North Carolina
Sponsor:: Duke University

Titles on ClinicalTrials.gov

Brief title: Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans

Official title: Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans

NCT05120635 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Video game play to alleviate adolescent anxiety

Children and teens · Anxiety in general or mixed

What is tested:: Eco-Rescue, Bejelewed 3
Who can join:: Ages 11 to 15 · Anxiety, Anxiety Disorders and Symptoms
Where:: 1 US site in Florida · also Israel, Switzerland
Sponsor:: School of Health Sciences Geneva

Titles on ClinicalTrials.gov

Brief title: Video Game Play to Alleviate Adolescent Anxiety

Official title: Evaluating the Effect of Gamified Cognitive Training and of Casual Videogame Play on Anxiety in Adolescents: Protocol for a Randomized Controlled Trial

NCT05923944 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Personalized artificial intelligence (AI)-driven models in cognitive behavioral therapy for anxiety

Generalized anxiety

What is tested:: Explicit CBT SAR Personalization for 6 weeks, Implicit CBT SAR Personalization for 6 weeks, Control CBT SAR for 6 weeks
Who can join:: Ages 18 and older · Generalized Anxiety Disorder (GAD)
Where:: 1 US site in California
Sponsor:: University of Southern California

Titles on ClinicalTrials.gov

Brief title: Personalized AI-Driven Models in Cognitive Behavioral Therapy for Anxiety

Official title: SCH: Personalized AI-Driven Models for Supporting User Engagement and Adherence in Health Interventions: Validation in Cognitive Behavioral Therapy for Anxiety

NCT07430800 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Brain activity changes after cognitive behavioral therapy for anxiety in autistic youth from high-need communities

Children and teens · Anxiety in general or mixed

What is tested:: Facing Your Fears (FYF) Intervention: A CBT Focused Group Treatment for Autistic Youth with Anxiety
Who can join:: Ages 8 to 14 · Autism Spectrum Disorder, Anxiety
Where:: 2 US sites in New Jersey, Pennsylvania
Sponsor:: Montclair State University

Titles on ClinicalTrials.gov

Brief title: Brain Activity Changes After Cognitive Behavioral Therapy for Anxiety in Autistic Youth From High-Need Communities

Official title: Electrophysiological Correlates of Anxiety-related Improvements Following Cognitive Behavioral Therapy for Autistic Youth in High-Need Communities

NCT06904508 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

The effects of audio-based therapy on anxiety in psoriasis

Anxiety in general or mixed

What is tested:: Music Therapy, Pink Noise
Who can join:: Ages 18 and older · Psoriasis (PsO), Anxiety
Where:: 1 US site in California
Sponsor:: University of California, San Francisco

Titles on ClinicalTrials.gov

Brief title: The Effects of Audio-Based Therapy on Anxiety in Psoriasis

Official title: The Effects of Audio-Based Therapy on Anxiety in Psoriasis

NCT07390487 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Developing resilience and anxiety management through the arts

Children and teens · Anxiety in general or mixed

What is tested:: Improvisation + Wellness, Improvisation, Social Craft
Who can join:: Ages 8 to 17 · Anxiety, Depression
Where:: 1 US site in Ohio
Sponsor:: Case Western Reserve University

Titles on ClinicalTrials.gov

Brief title: Developing Resilience and Anxiety Management Through the Arts

Official title: Developing Resilience and Anxiety Management Through the Arts (DRAMA) 2

NCT07033052 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Parent-based treatment for adolescent anxiety

Children and teens · Anxiety in general or mixed

What is tested:: Supportive Parenting for Anxious Childhood Emotions (SPACE), Parent Educational Support (PES)
Who can join:: Ages 14 to 17 · Anxiety Disorder of Adolescence
Where:: 1 US site in Connecticut
Sponsor:: Yale University

Titles on ClinicalTrials.gov

Brief title: Parent-Based Treatment for Adolescent Anxiety

Official title: Testing a Novel Parent-Based Treatment for Adolescent Anxiety Disorders

NCT07219992 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Stepped care treatment for anxiety resilience

Generalized anxiety · Panic and agoraphobia · Social anxiety · Specific phobias · Separation anxiety and selective mutism · Children and teens

What is tested:: Relaxation and Mentorship Training (RMT), Stepped Care Targeting Exposure and Parenting for Anxiety (STEP-A)
Who can join:: Ages 7 to 17 · Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD)
Where:: 1 US site in Texas
Sponsor:: Andrew Wiese

Titles on ClinicalTrials.gov

Brief title: Stepped Care Treatment for Anxiety Resilience

Official title: Stepped Care Cognitive Behavioral Therapy for Children and Adolescents With Anxiety

NCT07228143 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Brain stimulation, device, or app

Pilot study of virtual reality therapy for students with anxiety

Anxiety in general or mixed

What is tested:: gameChange
Who can join:: Ages 18 to 30 · Anxiety
Where:: 1 US site in Texas
Sponsor:: The University of Texas Health Science Center, Houston

Titles on ClinicalTrials.gov

Brief title: Pilot Study of Virtual Reality Therapy for Students With Anxiety

Official title: Pilot Study of Virtual Reality Therapy for Students With Anxiety

NCT05319509 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Personalized mobile cognitive behavioral therapy application

Anxiety in general or mixed

What is tested:: Personalized MAYA Mobile App, General MAYA Mobile App
Who can join:: Ages 18 to 25 · Anxiety Disorders and Symptoms, Depression
Where:: 1 US site in New York
Sponsor:: Weill Medical College of Cornell University

Titles on ClinicalTrials.gov

Brief title: Personalized Mobile Cognitive Behavioral Therapy Application

Official title: Efficacy of Personalized Mobile Cognitive Behavioral Therapy Targeting Anxiety and Depression

NCT05699525 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Uncertainty and firearms: obtaining secure storage

Anxiety in general or mixed

What is tested:: Lethal Means Counseling (LMC), CBT for Uncertainty - Enhanced (CUE)
Who can join:: Ages 18 and older · Anxiety
Where:: 1 US site in Ohio
Sponsor:: Ohio State University

Titles on ClinicalTrials.gov

Brief title: Uncertainty and Firearms: Obtaining Secure Storage

Official title: A Brief Fear of Uncertainty-Focused Intervention as an Adjunct to Lethal Means Counseling

NCT05818696 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Online parent education for child anxiety

Children and teens · Anxiety in general or mixed

What is tested:: Project EMPOWER, Being Brave Parent Education, Sharing Feelings
Who can join:: Ages 18 and older · Anxiety Disorders
Where:: 1 US site in Massachusetts
Sponsor:: Massachusetts General Hospital

Titles on ClinicalTrials.gov

Brief title: Online Parent Education for Child Anxiety

Official title: Evaluating the Effects of Self-Guided Interventions for Parents of Young Children With Anxiety

NCT07153250 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Expressive writing on minority stressors among sexual minority veterans

Anxiety in general or mixed

What is tested:: Expressive Writing on Minority Stressors, Neutral Writing
Who can join:: Ages 18 and older · Depressive Symptoms, Anxiety
Where:: 1 US site in Massachusetts
Sponsor:: U.S. Department of Veterans Affairs (VA) Office of Research and Development

Titles on ClinicalTrials.gov

Brief title: Expressive Writing on Minority Stressors Among Sexual Minority Veterans

Official title: Expressive Writing to Reduce Depressive and Anxiety Symptoms Among Sexual Minority Veterans

NCT05897021 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Computer-based treatment for social anxiety disorder

Social anxiety

What is tested:: Computer-Based Treatment
Who can join:: Ages 18 to 60 · Social Anxiety Disorder
Where:: 1 US site in New York
Sponsor:: New York State Psychiatric Institute

Titles on ClinicalTrials.gov

Brief title: Computer - Based Treatment for Social Anxiety Disorder

Official title: Computer-Based Treatment for Social Anxiety Disorder, A Randomized Controlled Trial

NCT04663724 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Brain stimulation, device, or app

Modulating anxious coping

Anxiety in general or mixed

What is tested:: Repetitive Transcranial Magnetic Stimulation (rTMS)
Who can join:: Ages 18 to 65 · Anxiety Disorders
Where:: 1 US site in South Carolina
Sponsor:: Medical University of South Carolina

Titles on ClinicalTrials.gov

Brief title: Modulating Anxious Coping

Official title: Modeling and Modulating Mechanisms of Escape, Avoidance, and Approach in the Anxiety Disorder Spectrum

NCT04824105 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Very brief exposure: development of a novel exposure modality for social anxiety disorder in transition-age youth

Social anxiety · Children and teens

What is tested:: Very Brief Exposure to Facial Expressions
Who can join:: Ages 16 to 22 · Social Anxiety Disorder
Where:: 1 US site in California
Sponsor:: Children's Hospital Los Angeles

Titles on ClinicalTrials.gov

Brief title: Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth

Official title: Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth

NCT06526260 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Mobile CBT for middle aged and older adults

Older adults · Anxiety in general or mixed

What is tested:: MAYA Mobile Application
Who can join:: Ages 40 and older · Anxiety Disorders and Symptoms, Depressive Symptoms
Where:: 1 US site in New York
Sponsor:: Weill Medical College of Cornell University

Titles on ClinicalTrials.gov

Brief title: Mobile CBT for Middle Aged and Older Adults

Official title: Feasibility and Acceptability of a Mobile Cognitive Behavior Therapy App Targeting Depression and Anxiety in Older Adults

NCT05754151 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Other

The impact of melatonin lotion on sleep and mental health

With another health condition · Anxiety in general or mixed

What is tested:: Melatonin lotion
Who can join:: Ages 18 to 21 · Sleep Problems, Depressive Disorder and Anxiety Disorders
Where:: 1 US site in California
Sponsor:: University of Redlands

Titles on ClinicalTrials.gov

Brief title: The Impact of Melatonin Lotion on Sleep and Mental Health

Official title: The Impact of Melatonin Lotion on Actigraphy, Sleep Quality, Autonomic Nervous System Indicators, Mood, Anxiety Symptoms, and Side Effects

NCT06768749 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Reaching Calm: a digital intervention to prevent perinatal anxiety disorders

Pregnancy and postpartum · Anxiety in general or mixed

What is tested:: Digital mental health intervention
Who can join:: Ages 18 and older · Female participants only · Perinatal Anxiety, Anxiety Sensitivity
Where:: 1 US site in Massachusetts
Sponsor:: University of Massachusetts, Worcester

Titles on ClinicalTrials.gov

Brief title: Reaching Calm: A Digital Intervention to Prevent Perinatal Anxiety Disorders

Official title: Reaching Calm Pilot (K23)

NCT07458698 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

Mindful self-compassion for anxiety disorders and depression

Generalized anxiety · Panic and agoraphobia · Social anxiety

What is tested:: Mindful Self-Compassion
Who can join:: Ages 18 to 75 · Anxiety Disorders, Generalized Anxiety Disorder
Where:: 1 US site in District of Columbia
Sponsor:: Georgetown University

Titles on ClinicalTrials.gov

Brief title: Mindful Self-Compassion for Anxiety Disorders and Depression

Official title: Mindful Self-Compassion for Anxiety Disorders and Depression

NCT05671419 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Other

Prediction of anxiety and memory state

With another health condition · Anxiety in general or mixed

What is tested:: CAMERA (Context-Aware Multimodal Ecological Research and Assessment)
Who can join:: Ages 18 to 55 · Anxiety, Memory
Where:: 1 US site in New York
Sponsor:: Columbia University

Titles on ClinicalTrials.gov

Brief title: Prediction of Anxiety and Memory State

Official title: Developing the Context-Aware Multimodal Ecological Research and Assessment (CAMERA) Platform for Continuous Measurement and Prediction of Anxiety and Memory State

NCT06551090 on ClinicalTrials.gov

RecruitingNo phase (therapy or device study)Therapy, behavioral, or digital

MH-POWER for college students on the spectrum

Panic and agoraphobia

What is tested:: The MH-POWER program
Who can join:: Ages 18 to 30 · Autistic College Students With Anxiety, Depression, Stress
Where:: 1 US site in Texas
Sponsor:: University of Texas Rio Grande Valley

Titles on ClinicalTrials.gov

Brief title: MH-POWER for College Students on the Spectrum

Official title: Empowering Autistic College Students: Mental Health Skill Building at a Hispanic-Serving Institution

NCT07682753 on ClinicalTrials.gov

Showing 50 of 50 studies · data from the ClinicalTrials.gov public data service, fetched October 8, 2026

See all 1,208 on ClinicalTrials.gov →

Recruiting, interventional studies (Phase 2, 3, or 4 studies, plus therapy and device studies that have no phase) whose title and listed conditions are about an anxiety disorder (not anxiety about surgery, a dental visit, a scan, or another procedure) and that have at least one US site, leaving out programs whose late-stage trials failed and records that look out of date (primary completion date passed and no update in the past 6 months). Up to 50 are shown, balanced across anxiety types and treatment kinds (at most 2 per main intervention), then ranked by phase, number of US sites, and size. Phase 1 safety studies and studies with no US site are left out here but appear on ClinicalTrials.gov. Study details change often; always check the study page and contact the study team to confirm who can join. This site does not enroll anyone.

How to use this page

Questions worth bringing to the appointment

Based on NICE guidance on what to discuss

What benefit should I expect, and how long until it takes full effect?
What side effects are common, and what should I do if I get them?
Could it make me feel more anxious, agitated, or sleepless at first?
Does it interact with my other medicines, alcohol, or supplements?
Is there a withdrawal effect if I miss doses or stop?
How long should I keep taking it after I feel better?